secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001104659-25-004953
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BCLI fails to regain Nasdaq MVLS compliance; delisting stayed pending Feb 25 hearing
--------------------------------------------------------------------------------

- Company previously failed to meet Nasdaq's minimum market value of listed securities requirement by Jan 14, 2025.
- On Jan 21, 2025, submitted a hearing request to appeal the Staff's delisting determination.
- Nasdaq confirmed hearing on Feb 25, 2025; delisting action is stayed pending final Panel decision.
- Company will present plan to regain compliance and sustain long-term listing criteria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925004953/0001104659-25-004953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925004953/tm254046d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-004953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer